Deep Science Ventures

Dunia Innovation is developing the world's first self-driving laboratory aimed at advancing electrocatalytic carbon dioxide utilization. This innovative facility is designed to significantly accelerate catalyst research, addressing the challenges associated with scalable carbon utilization. By focusing on creating a circular carbon economy, Dunia Innovation seeks to transform carbon dioxide into valuable chemicals and fuels. This approach not only helps businesses understand their carbon footprints but also supports the broader goal of achieving net-zero emissions by reducing overall emissions.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Bastion Therapeutics is a preclinical stage biotechnology startup focused on developing innovative anti-inflammatory cell therapies. The company utilizes proprietary platform technology to enhance regulatory T cells (Tregs) within the immune system. By targeting neuroinflammation in the central nervous system, Bastion's therapies aim to protect neurons and improve synaptic connectivity. This approach seeks to help patients maintain cognitive function and prevent its decline, addressing significant challenges in neurodegenerative conditions.

Xonai is a software development company that focuses on accelerated computing for data processing platforms. It has developed a fully automated hardware selection and data management platform aimed at establishing a universal and flexible infrastructure for cloud computing. Xonai's technology optimizes data infrastructure, which helps organizations reduce their cloud expenses while improving the efficiency of data software. This allows businesses that rely on scaling data and AI-driven products to cut costs and enhance their time to value.

Antiverse is an innovative antibody discovery company that aims to accelerate drug development through its advanced platform. By integrating structural biology, machine learning, and medicine, Antiverse provides solutions to predict antibody-antigen binding and identify potential antibody drug candidates for challenging targets. The company employs machine learning and cell-free protein synthesis to enhance the prediction of antibody affinity for specific antigen targets, allowing pharmaceutical companies and contract research organizations to expedite the antibody hit discovery process. Antiverse is committed to transforming drug development and improving patient outcomes.

Rhizocore Technologies produces locally-adapted mycorrhizal fungi to enhance tree planting success.

Holy Grail is engaged in the development of advanced air carbon capture technology, focusing on capturing carbon dioxide from the atmosphere and permanently storing it above ground. The company's innovative device utilizes electrons to extract CO2 from large centralized emitters, contributing to efforts in mitigating climate change. In addition to carbon capture, Holy Grail is involved in research and engineering related to various products, including batteries and catalysts. This work enables industrial clients to optimize energy efficiency and economic performance by cross-validating predictions and simulations with experimental data. Through its initiatives, Holy Grail aims to play a significant role in reducing atmospheric carbon levels and promoting sustainable practices.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

Mission Zero specializes in developing direct air capture technology that effectively removes carbon dioxide from the atmosphere and concentrates it for various sequestration pathways. The company's innovative system allows for the efficient recovery of historic carbon dioxide at any scale. By utilizing a process that involves pulling air into a device and dissolving the carbon in a water solvent, Mission Zero can release the carbon as gas through electrodialysis. This technology not only facilitates the production of low-energy and clean carbon dioxide but also aims to provide affordable carbon capture services, contributing to an environment with reduced air pollution.

Holy Grail is engaged in the development of advanced air carbon capture technology, focusing on capturing carbon dioxide from the atmosphere and permanently storing it above ground. The company's innovative device utilizes electrons to extract CO2 from large centralized emitters, contributing to efforts in mitigating climate change. In addition to carbon capture, Holy Grail is involved in research and engineering related to various products, including batteries and catalysts. This work enables industrial clients to optimize energy efficiency and economic performance by cross-validating predictions and simulations with experimental data. Through its initiatives, Holy Grail aims to play a significant role in reducing atmospheric carbon levels and promoting sustainable practices.

Mytos is focused on creating a fully automated cell manufacturing platform tailored for the biotech sector, specifically targeting the drug development industry. The company's technology employs automation to enhance the production of human cells, facilitating more efficient and adaptable cell culture processes. This innovative approach allows scientists to modify culturing protocols easily, leading to faster progress in cell growth and development. By streamlining these processes, Mytos aims to support pharmaceutical and biotech businesses in their research and production efforts.

New Motion Labs (NML) is a mechanical engineering intellectual property licensing business based in the United Kingdom that specializes in the development and licensing of innovative sprocket tooth profiles for sprocket manufacturers. Their technology, known as Enduo, revolutionizes the conventional chain drive system by shifting the power transfer method to dual point engagement on both sides of the sprocket tooth. This advancement significantly enhances the durability of chain drives, allowing them to last up to 3.5 times longer while also reducing energy losses by 50%. The new sprocket tooth profile minimizes wear by eliminating relative movement over the teeth under load, which decreases friction and increases overall drivetrain efficiency. Additionally, NML's technology is designed to be retrofittable to existing applications, providing a lightweight and efficient solution for users looking to improve their drivetrain systems.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.